Multi Commodity Exchange of India consolidated net profit rises 83.19% in the June 2025 quarter
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
a minute ago
- Time of India
Strong APSEZ performance, Adani's transition to non-executive director gets analyst backing
New Delhi: Adani Ports and Special Economic Zone's (APSEZ) robust first quarter revenue growth and margin improvement across major business verticals won the backing of leading brokerages, who saw the company as a long-term proxy for India's trade and infrastructure growth. Leading brokerages, including Goldman Sachs, HSBC, Kotak, and Jefferies, have issued a unanimous 'BUY' rating on APSEZ, as a positive sentiment followed a robust first-quarter performance. The company also announced that Gautam Adani will cease to be a Key Managerial Personnel (KMP) and will now serve as the non-executive chairman, transitioning from his earlier role as Executive Chairman. In a note, Jefferies said Q1 EBITDA was 14 per cent above its estimates, led by domestic ports margin improvement and 2.0-2.9 times year-on-year revenue rise in logistics and marine. "Management reiterated its focus on absolute EBITDA growth, as the company intends to deliver end-to-end solutions vs pure volume growth," it said, adding FY26 volume guidance at 505-515 million tonnes (12-14 per cent rise yoy) was maintained. HSBC Global Investment Research said the company delivered robust Q1 revenue growth and margin improvements across major business verticals. "Strong ramp-up of new assets, turnaround in international port and logistics margins underscore intact earnings trajectory." Port throughput grew 11 per cent to 121 million tonnes, backed by 6 per cent growth in domestic and a 4 times jump in international. New asset additions (Vizhinjam and Gopalpur) offset weakness in Mundra, which saw a 6 per cent throughput decline due to geopolitical restrictions and embargoes, and softer coal handling due to lower thermal energy demand. "We lift FY26-28 EBITDA (estimate) by 2 per cent, reflecting better-than-expected margin improvement," it said, adding Vizhinjam and Colombo terminals should strengthen its capacity and pricing power. Goldman Sachs said while tariff-related uncertainty will remain, APSEZ's strong portfolio of port assets leverages it for market share gains (as ports of Vizinjham, Colombo and Tanzania ramp up in FY26 and Gangavaram regains its volumes), resulting in 12.5 per cent volume growth. Kotak Institutional Equities said APSEZ grew its EBITDA 30 per cent year-on-year, while facing head-on specific issues on imported coal and the transhipment business. "The port business continues to expand margins. It continues to add brownfield capacities judiciously and make its presence felt in new markets." Reported financial numbers came in better than expectations. Logistics and Marine revenue drove the growth, analysts at Goldman Sachs said in their report. For the quarter, the company reported a 21 per cent year-on-year increase in revenue to Rs 9,126 crore, while net profit rose 6.5 per cent to Rs 3,314.6 crore compared to the same period last year. Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) rose 13 per cent to Rs 5,494 crore, although margins narrowed to 60.2 per cent from 64.1 per cent in the same quarter last year. APSEZ has given a revenue guidance of Rs 36,000 crore to Rs 38,000 crore for the current fiscal (FY26) and an EBITDA forecast of Rs 21,000 crore to Rs 22,000 crore. The capex estimate has been put at Rs 11,000 crore to Rs 12,000 crore. "Strong ramp-up of new assets and a turnaround in international port and logistics margins underscore an intact earnings trajectory," said HSBC. Jefferies appreciated the management's continued focus: "Management reiterated its commitment to absolute EBITDA growth as the company shifts towards delivering end-to-end solutions, rather than purely volume-driven growth." PTI ANZ DR DR
Economic Times
a minute ago
- Economic Times
Signature Global reports 386% year-on-year increase in Q1 profit after tax
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Realty developer Signature Global has reported a 386% year-on-year increase in profit after tax (PAT), reaching Rs 34 crore in Q1 FY26 compared to Rs 7 crore in Q1 growth was primarily driven by increased revenue recognition, which rose by 118% to Rs 870 crore from Rs 400 crore in the same quarter last year, owing to higher project completions. The company has cumulatively delivered 15.7 million sq. ft. of real estate development till Q1 company achieved pre-sales of Rs 2,640 crore in Q1 FY26 versus Rs 3,120 crore in Q1 FY25. Average sales realization improved significantly to Rs 16,296 per sq ft from Rs 12,457 per sq ft in FY25. Collections for the quarter stood at Rs 930 crore compared to Rs 1,210 crore in Q1 FY25. Net debt remained stable at Rs 890 terms of profitability ratios, the company reported an adjusted gross profit margin of 27% in Q1 FY26 against 28% in Q1 FY25, while adjusted EBITDA margin stood at 12% compared to 13% in the previous line with its long-term growth strategy, Signature Global acquired 9.96 acres of land in its key micro-market of Sohna during Q1 FY26. The land parcel offers a development potential of approximately 0.53 million sq. ft."Building on the strong momentum of FY25, we delivered a robust performance in the first quarter of FY26, with our operational revenue doubling year-on-year. This growth reflects our continued focus on customer satisfaction and the timely delivery of quality homes. With several new project launches planned in the coming quarters, we are well-positioned to sustain this growth trajectory and further strengthen our market presence,' said Pradeep Kumar Aggarwal, Chairman and Whole- Time Global holds a market share of 13% in the National Capital Region (NCR) and 20% share in Gurugram within the price range of Rs 2 crore to Rs 5 of Q1FY26, the company has successfully delivered 15.7 million sq. ft. of real estate. Its project pipeline remains robust, comprising 17.1 million sq. ft. of recently launched projects, 24.5 million sq. ft. of forthcoming developments, and 9.2 million sq. ft. of ongoing construction, all slated for execution over the next 2–3 years.
Time of India
5 minutes ago
- Time of India
Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 months
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel US drugmaker Eli Lilly 's weight-loss drug Mounjaro (tirzepatide) has crossed Rs 100 crore in sales in India in just four months of launch, making it one of the country's fastest-growing prescription brands ever by drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker this month-on-month doubling of sales continues, Mounjaro's revenue could cross Rs 500 crore by March, experts that, there could be a price erosion in the segment, as generic versions of rival GLP1 molecule semaglutide, branded as Wegovy by Danish drugmaker Novo Nordisk, are expected to flood the that have seen similar burgeoning growth in the past include some in the anti-diabetic category, such as Januvia (sitagliptin), Trajenta (linagliptin), Jardiance (empagliflozin), Forxiga (dapagliflozin), and Rybelsus (oral semaglutide).Wegovy, launched in early June, also saw a doubling of sales numbers with cumulative sales of the first two months at Rs 10 crore.'Though Wegovy has a strong prescriber base because of Rybelsus (oral semaglutide), substantial promotion may be needed to reach the Mounjaro patient base for the injectable market,' said Sheetal Sapale, vice president, commercial, at which was launched in late March, has so far garnered a significant patient base, selling about 160,000 units versus Wegovy's 5,000.'As competition gets tough and branded generics come into the market, volume sales will be a major decider of who goes ahead in the race as this extent of value creation will be challenging,' Sapale experts and doctors said the higher weight loss efficacy of 20-22% from Mounjaro compared to Wegovy's 16-18% and a lower price point make it more attractive to many is currently priced between Rs 17,345 to Rs 26,050 per pen-filled injection, which is a month's dose of four once-a-week shots. Mounjaro, which is also given on a weekly basis, is priced at Rs 14,000 to Rs 17,500 for a month's Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai, said Mounjaro has captured a major share of the market so far due to their early launch and higher weight loss efficacy.'Diabetes patients prefer Wegovy, while non-diabetes obese patients prefer Mounjaro,' he from chronic weight management in obesity, Mounjaro is also indicated to improve glycaemic control in adults with type-2 diabetes mellitus, which is an additional benefit. Wegovy is used for obesity treatment and selectively in reduction in risk of major adverse cardiovascular events (MACE).
